바이오엑스셀코리아
- 등록2026.02.25
- 조회33
InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar)
- 분류 시약 > Antibody
- 브랜드Bioxcell
- 원산지USA
- 이메일 bioclone@bioclone.co.kr
- 연락처 02-2690-0058
BioXCell 은
In Vivo용 Antibody를 1mg,5mg,25mg,50mg,100mg
용량으로 직접 제조하며, 합리적인 가격으로
공급하는 회사입니다.
BioXCell Biosimilars "InVivoSIM™"
InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar)
Catalog # SIM0009
SIZE: 1mg,5mg,25mg,50mg,100mg
Product Description
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Atezolizumab making it ideal for research use. This Atezolizumab biosimilar reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. PD-L1 is expressed on T lymphocytes, B lymphocytes, NK cells, dendritic cells, as well as IFNγ stimulated monocytes, epithelial cells and endothelial cells. PD-L1 binds to its receptor, PD-1, found on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Engagement of PD-L1 with PD-1 leads to inhibition of TCR-mediated T cell proliferation and cytokine production. PD-L1 is thought to play an important role in tumor immune evasion. Induced PD-L1 expression is common in many tumors and results in increased resistance of tumor cells to CD8 T cell mediated lysis. Atezolizumab blocks the interaction of PD-L1 with PD-1 and CD80.
Specifications
| Isotype | Human IgG1 |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG1 (N297A) isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Conjugation | This product is unconjugated. Conjugation is available via our Antibody Conjugation Services. |
| Mutations | N297A |
| Immunogen | Not available or unknown |
| Reported Applications | in vivo PD-L1 blockade Flow Cytometry Western Blot |
| Formulation | PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin | ≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Purity | ≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Purification | Protein A |
| RRID | AB_2894730 |
| Molecular Weight | 150 kDa |
| Murine Pathogen Tests | Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |
Application References
in vivo PD-L1 blockade
Deng R, Tian R, Li X, Xu Y, Li Y, Wang X, Li H, Wang L, Xu B, Yang D, Tang S, Xue B, Zuo C, Zhu H (2024). "ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis" iScience 27(4):10953
PubMed
in vitro PD-L1 blockade
Sun R, Meng Z, Lee H, Offringa R, Niehrs C (2023). "ROTACs leverage signaling-incompetent R-spondin for targeted protein degradation" Cell Chem Biol 30(7):739-752.e8.
PubMed
in vitro PD-L1 blockade
Zhao Y, Caron C, Chan YY, Lee CK, Xu X, Zhang J, Masubuchi T, Wu C, Bui JD, Hui E (2023). "cis-B7:CD28 interactions at invaginated synaptic membranes provide CD28 co-stimulation and promote CD8+ T cell function and anti-tumor immunity" Immunity 56(6)
PubMed
in vivo PD-L1 blockade
Lee DH, Ahn H, Sim HI, Choi E, Choi S, Jo Y, Yun B, Song HK, Oh SJ, Denda-Nagai K, Park CS, Irimura T, Park Y, Jin HS (2023). "A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity" J Exp Clin
PubMed
Product Citations
- Cancer Research
Functional Role of NOXA in Hypoxia-Mediated PD-L1 Inhibitor Response in Hepatocellular Carcinoma.
In Int J Mol Sci on 16 May 2025 by Huang, M., Lan, T., et al.
PubMed
- Cancer Research
- Immunology and Microbiology
Kynurenine promotes the immune escape of colorectal cancer cells via NAT10-mediated ac4C acetylation of PD-L1.
In Clinics (Sao Paulo) on 18 April 2025 by Wang, Z., Yin, M., et al.
PubMed
Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMB
In medRxiv on 27 February 2025 by Zemp, F. J., Breckenridge, Z., et al.
- Cancer Research
- Immunology and Microbiology
ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/β-catenin/PD-L1 axis.
In iScience on 19 April 2024 by Deng, R., Tian, R., et al.
PubMed
더욱 다양한 바이오시밀러 제품 문의는 바이오클론(주) 로 연락 부탁 드립니다!
매주 월, 목요일 4시 발주 1주 소요
자세한 문의사항은 본사로 문의해 주시기 바랍니다.
바이오클론(주)
******* Bio X Cell 과 바이오클론(주) 의 기술 서비스 운영이 통합(합병)됨에 따라,
2026년 2월 19일부로 모든 Tech 문의, 견적, 발주 등은 바이오클론(주)에서 일괄 담당합니다. *******
이에 관련 문의는 아래 바이오클론 연락처로 부탁 드립니다. 서비스 제공 범위 및 지원 절차는 기존과 동일합니다.
E-mail: bioclone@bioclone.co.kr / Tel: 02-2690-0058
biosimilar
bioxcell
invivo
antibody
Atezolizumab
- Bispecific anti-mouse PD-1 x anti-mouse VEGF-A (LALA-PG) 2026.03.06
- InVivoSIM anti-human CD38 (Isatuximab Biosimilar) 2026.03.05
- InVivoSIM bispecific anti-human CD3 x CD20 (Epcoritamab Biosimilar) 2026.03.04
- InVivoSIM anti-human CD38 (Isatuximab Biosimilar) 2026.03.03
- InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) 2026.03.03
- InVivoSIM anti-human PD-L1 (Atezolizumab Biosimilar) 2026.02.26
- InVivoSIM bispecific anti-human CD3 x CD20 (Epcoritamab Biosimilar) 2026.02.24
- InVivoMAb human IgG1 isotype control 2026.02.23
- InVivoSIM anti-human ActRIIA (ACVR2A), ActRIIB (ACVR2B) (Bimagrumab Biosimilar) 2026.02.23
- InVivoSIM anti-human ActRIIA (ACVR2A), ActRIIB (ACVR2B) (Bimagrumab Biosimilar) 2026.02.20
